budesonide/formoterol (Symbicort)

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Mild or Moderate Asthma

Conditions

Mild or Moderate Asthma

Trial Timeline

Oct 1, 2003 → Feb 1, 2005

NCT ID

NCT00646516

About budesonide/formoterol (Symbicort)

budesonide/formoterol (Symbicort) is a phase 3 stage product being developed by AstraZeneca for Mild or Moderate Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00646516. Target conditions include Mild or Moderate Asthma.

What happened to similar drugs?

8 of 16 similar drugs in Mild or Moderate Asthma were approved

Approved (8) Terminated (2) Active (7)

✅Aricept (donepezil hydrochloride) + placeboEisaiApproved

✅Donepezil HClEisaiApproved

✅ElagolixAbbVieApproved

✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ElidelBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00646516	Phase 3	Completed	Oct 1, 2003	Feb 1, 2005	Mild or Moderate Asthma

Competing Products

20 competing products in Mild or Moderate Asthma

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	32
Ranirestat + Placebo	Eisai	Phase 2/3	38
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	43
Donepezil HCl	Eisai	Approved	43
Donanemab + Aducanumab	Eli Lilly	Phase 3	40
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	35
Elagolix	AbbVie	Approved	35
AZD1446 + Placebo	AstraZeneca	Phase 2	35
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	29
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	43
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	35
MK-8931	Merck	Phase 1	29
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	32
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	43
LCZ696 + Sildenafil	Novartis	Phase 2	35
QCZ484 + Placebo	Novartis	Phase 1	29
Rivastigmine Patch	Novartis	Approved	43
AFQ056	Novartis	Phase 1	29
Canakinumab	Novartis	Phase 2	27